Edition:
United Kingdom

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

5.02USD
23 Feb 2018
Change (% chg)

$0.22 (+4.58%)
Prev Close
$4.80
Open
$4.87
Day's High
$5.03
Day's Low
$4.73
Volume
201,745
Avg. Vol
306,233
52-wk High
$9.25
52-wk Low
$3.95

Select another date:

Fri, Feb 16 2018

BRIEF-Great Point Partners Opposes Biocryst Pharma Proposed Merger With Idera Pharma

* GREAT POINT PARTNERS LLC OPPOSES THE BIOCRYST PHARMACEUTICAL PROPOSED MERGER WITH IDERA PHARMACEUTICALS, INC.

BRIEF-Great Point Reports 7.60 Pct Stake In BioCryst Pharmaceuticals

* GREAT POINT PARTNERS, LLC REPORTS 7.60 PERCENT STAKE IN BIOCRYST PHARMACEUTICALS INC AS OF FEBRUARY 6, 2018 - SEC FILING‍​ Source text: (http://bit.ly/2HjJO7H) Further company coverage:

BRIEF-Biocryst Pharma And Idera Pharma Sign Merger Agreement To Form New Company

* BIOCRYST PHARMACEUTICALS AND IDERA PHARMACEUTICALS ANNOUNCE MERGER TO COMBINE CAPABILITIES TO SERVE MORE PATIENTS WITH RARE DISEASES

BRIEF-Biocryst Advancing Potential Treatment For Rare And Severely Debilitating Fibrodysplasia Ossificans Progressiva

* BIOCRYST ADVANCING POTENTIAL TREATMENT FOR RARE AND SEVERELY DEBILITATING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA

BRIEF-BioCryst Pharma files for mixed shelf of up to $200 million‍​

* Files for mixed shelf of up to $200 million - SEC filing‍​ Source text: (http://bit.ly/2m4wZHE) Further company coverage:

BRIEF-BioCryst Pharmaceuticals reports Q3 loss per share of $0.18

* Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S

BRIEF-Biocryst’s Rapivab receives FDA approval for a pediatric indication

* Biocryst’s Rapivab (peramivir injection) receives FDA approval for a pediatric indication

BRIEF-Biocryst Pharmaceuticals prices public offering of common stock

* Biocryst Pharmaceuticals prices public offering of common stock

BRIEF-BioCryst Pharmaceuticals announces underwritten public offering​

* BioCryst Pharmaceuticals Inc - ‍offering to sell $80 million of its common stock in an underwritten public offering​

BRIEF-Biocryst announces positive results from mid-stage HAE trial

* Biocryst announces positive results from its Apex-1 Phase 2 trial in HAE

Select another date: